Author/Authors :
Kim، Sun-Ouck نويسنده Department of Urology, Chonnam National University Medical School, Gwangju, South Korea. , , Choi، Hyang Sik نويسنده Department of Urology, Chonnam National University Medical School, Gwangju, South Korea. , , Kwon، Dongdeuk نويسنده Department of Urology, Chonnam National University Medical School, Gwangju, South Korea ,
Abstract :
Purpose: Nocturia is the main cause of disturbance of sleep maintenance and negatively
impacts quality of life (QoL). We assessed the effects of the ?1-adrenoceptor antagonist, tamsulosin,
on nocturia and quality of sleep, for the treatment of lower urinary tract symptoms
(LUTS) in women with a maximal flow rate (Qmax) less than 15 mL/sec.
Materials and Methods: From January 2008 to December 2009, women with LUTS [Qmax ?
15 mL/s, International Prostate Symptom Score (IPSS) ? 8] and nocturia (void/night ? 1) were
selected for this study. Two hundred ninety six patients completed voiding diary, a questionnaire
on the Medical Outcomes Study (MOS) sleep scale and underwent follow-up evaluation
after 4 weeks of treatment (tamsulosin, 0.2 mg, once daily). Effectiveness was assessed by
analysis of the IPSS, the bother score, the Qmax, and postvoid residual urine (PVR).
Results: The mean number of voids per night was 2.66 ± 1.3, and the total IPSS and bother
scores were 15.2 ± 8.9 and 3.4 ± 1.2, respectively. Clinical parameters, including the IPSS,
the bother score, the Qmax and the PVR, improved significantly from baseline after treatment
(P < .05). The change in nocturia was -1.12 (P < .05). Concerning sleep quality, the sleep
problem index showed a significant decrease. Among the items on the sleep subscale, sleep
disturbance, somnolence, and sleep adequacy were significantly changed (P < .05).
Conclusion: The ?1-adrenoceptor antagonist tamsulosin significantly improved nocturia and
sleep quality as well as LUTS in women with low Qmax
